| NeuroMetrix develops and commercializes health care products that utilize non-invasive neurostimulation. Co. designs, builds and markets medical devices that stimulate nerves and analyzes nerve response for diagnostic and therapeutic purposes. Co.'s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Co.'s marketed products include: DPNCheck, which is a nerve conduction test that is used to evaluate evaluate peripheral neuropathies such as diabetic peripheral neuropathy; Quell, which is a wearable device for symptomatic relief of chronic pain; and ADVANCE System, which is a platform for the performance of nerve conduction studies. We show 22 historical shares outstanding datapoints in our NURO shares outstanding history coverage, used to compute NURO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NURO market cap history over the course of time is important for investors
interested in comparing NURO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NURO versus a peer is one thing; comparing
NURO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NURO can fluctuate over the course of history.
With this page we aim to empower investors researching NURO by allowing them to research the NURO market cap history.